SCHEMBL3399744

SCHEMBL3399744

CCn1c(-c2cccc3ccccc23)nc(Cl)c1C(=O)N1CCN(C2CCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.47
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
UBE2N P61088 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HIF1A Q16665 1/20 0.40
ACACB O00763 3/20 0.40
ACACA Q13085 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405408 0.98 HTR2C (0.47) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3401043 0.90 HTR2C (0.56) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3402170 0.89 HTR2C (0.47) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3405387 0.89 HTR2C (0.56) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3404758 0.87 HTR2C (0.47) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3405306 0.86 HTR2C (0.45) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3401298 0.85 HTR2C (0.46) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3405656 0.83 HTR2C (0.45) HTR2CLMNAKDM4EALDH1A1POLB
SCHEMBL3402695 0.83 HTR2C (0.56) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL3401027 0.83 HTR2C (0.46) HTR2CSMN1; SMN2LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
EP-1848428-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-10-31 EP disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 HTR2C 416/4885SMN1; SMN2 1605/4885LMNA 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.